Every Cure and BioPhy launch partnership on drug repurposing
EveryCure will leverage BioLogicAI, BioPhy’s predictive AI engine, to assess drug-disease matches
Read more..."It's a simple story, we liked the team.. we liked the opportunity," said Jeremy Liew, partner at Lightspeed Venture Partners. "This opportunity for white-label social networks is actually a very compelling one as we've seen the growth of those social networks, now more than a million on Ning."
Liew, who was a panelist at AlwaysOn's Summit at Stanford this week, was responding to a question asked by Michael Arrington of TechCrunch, who was sitting in the audience. Arrington asked why Lightspeed invested $15 million in Ning at a seemingly absurd valuation of $750 million, a deal first reported by All Things D.
Liew also likened Lightspeed's investment in Ning to Greylock's $25 million investment in Facebook at a $500 million valuation back in 2006.
Watch the video for more of Liew's explanation.
Founder and CEO of Vator, a media and research firm for entrepreneurs and investors; Managing Director of Vator Health Fund; Co-Founder of Invent Health; Author and award-winning journalist.
All author postsEveryCure will leverage BioLogicAI, BioPhy’s predictive AI engine, to assess drug-disease matches
Read more...The contract will make it easier for state agencies to evaluate and implement Fusion's technology
Read more...The new office marks OpenAI's first location in Asia
Read more...Joined Vator on